Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus
Pooled result · TIA/strokeResult — go to the resultRelative risk 0.840 95% CI 0.759–0.936Authors' conclusion
Improvements in A1c with GLP-1RA were associated with stroke prevention in patients with diabetes and with TIA or stroke. Reductions in cardiovascular mortality include therapy with GLP-1RA and SGLT2i. Aggressive lowering of A1c, however, was associated with increased CVD.
Study context
- Population
- Patients with DM in trials of glucose-lowering agentsreviews and meta-analyses
- Participants
- 46,541 / 46,959 / 26,223 / 5,238
- Comparison
- Glucose-lowering agent classes for TIA/stroke prevention
- GLP-1RAn = 46,541
- SGLT2in = 46,959
- IPn = 26,223
- Thiazolidinediones (TZD)n = 5,238
- Outcome
- TIA/stroke
Pooled result
As reported in the abstract
Relative risk
0.840
95% CI 0.759–0.936
P = 0.001
GLP-1RA
RR 0.840 (95% CI 0.759–0.936); P = 0.001
Further pooled results
Cardiovascular death
| RR (CI) | P value | ||
|---|---|---|---|
| GLP-1RA | 0.873 (0.804–0.947) | P = 0.001 | |
| SGLT2i | 0.835 (0.706–0.987) | P = 0.034 | |
| 0.512Relative risk (log scale) |
Hospitalisation for HF
| RR (CI) | P value | ||
|---|---|---|---|
| SGLT2iDecreased only with SGLT2i | 0.699 (0.626–0.781) | P < 0.001 | |
| 0.512Relative risk (log scale) |
Major adverse cardiovascular events (MACE)
- Reductions in MACE for each class
Cardiovascular death
- Not decreased with TZD or IP
Correlation of increased cardiovascular death with aggressive A1c lowering
- R (P =.012)
- −0.611
GLP-1RA: correlation of decreased stroke RR with A1c decreases
- R (P =.010)
- 0.917
Safety
- Trend of cardiovascular death with RR of hypoglycaemia, r (P =.08)
- 0.447
- No increase in hypoglycaemia with GLP-1RA
Original publication
Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus. Endocr Pract. Published 13 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →